Eli Lilly developed Mounjaro and Zepbound, helping the pharmaceutical company become one of the world’s most valuable businesses by market capitalization.
Eli Lilly and Company was founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Union army veteran. The company initially emphasized medicines made with reliable ingredients and consistent manufacturing methods.
Mounjaro is the brand name for tirzepatide used for type 2 diabetes, while Zepbound is the brand name for tirzepatide approved for chronic weight management in eligible adults. Tirzepatide acts on GIP and GLP-1 hormone pathways. The U.S. Food and Drug Administration approved Mounjaro in 2022 and Zepbound in 2023.
Mounjaro and Zepbound are sometimes confused as separate drugs because they have different brand names and approved uses. They contain the same active ingredient, tirzepatide, but their labeling and indications differ. Eli Lilly also produces insulin, oncology medicines, and treatments for neurological conditions.